LMP7 Antibody (56-T): sc-100284

LMP7 Antibody (56-T) is a mouse monoclonal IgG2a antibody that detects LMP7 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). LMP7 is a crucial component of the proteasome, a multi-catalytic proteinase complex that plays a vital role in the regulated degradation of ubiquitinated proteins, thereby maintaining cellular homeostasis and regulating various cellular processes such as the cell cycle, apoptosis, and antigen presentation. The proteasome is located in both the nucleus and cytoplasm, where LMP7 forms a highly ordered ring-shaped structure composed of at least 15 nonidentical subunits. This structural organization is essential for function, as LMP7 allows for efficient processing of proteins into peptides that can be presented by major histocompatibility complex (MHC) molecules, particularly in immune responses. Upon stimulation with interferon-gamma, LMP7, along with LMP2, replaces housekeeping subunits in the proteasome, enhancing peptide generation that is critical for activating cytotoxic T cells. LMP7 expression in various tissues occurs in two forms—LMP7A and LMP7B—further underscoring importance in immune function and response to cellular stress. Through facilitating regulatory protein degradation, LMP7 remains integral to the immune system′s ability to respond to pathogens and maintain cellular integrity, making LMP7 a significant target for research in immunology and cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LMP7 Antibody (56-T) References:

1. Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis.  |  Mundt, S., et al. 2016. Eur J Immunol. 46: 104-13. PMID: 26464284
2. Immunoproteasome subunit LMP7 Deficiency Improves Obesity and Metabolic Disorders.  |  Kimura, H., et al. 2015. Sci Rep. 5: 15883. PMID: 26515636
3. Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis.  |  Hewing, B., et al. 2017. Sci Rep. 7: 13342. PMID: 29042581
4. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.  |  Basler, M., et al. 2018. EMBO Rep. 19: PMID: 30279279
5. LMP7 inhibits the activation of NLRP3 inflammasome through interaction with NLRP3.  |  Jin, J., et al. 2020. Biochem Biophys Res Commun. 531: 152-159. PMID: 32782149
6. LMP7 polymorphism may modify the presentation and clinical impact of minor histocompatibility antigens in matched related hematopoietic stem cell transplantation.  |  Mossallam, GI., et al. 2021. Cell Immunol. 364: 104329. PMID: 33798908
7. Airway epithelial immunoproteasome subunit LMP7 protects against rhinovirus infection.  |  Dimasuay, KG., et al. 2022. Sci Rep. 12: 14507. PMID: 36008456
8. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis.  |  Li, J., et al. 2023. Cardiovasc Res. 119: 1030-1045. PMID: 36464772
9. ONX0914 inhibition of immunoproteasome subunit LMP7 ameliorates diabetic cardiomyopathy via restraining endothelial-mesenchymal transition.  |  Wang, M., et al. 2023. Clin Sci (Lond). 137: 1297-1309. PMID: 37551616
10. PR-957 retards rheumatoid arthritis progression and inflammation by inhibiting LMP7-mediated CD4+ T cell imbalance.  |  Liu, Q., et al. 2023. Int Immunopharmacol. 124: 110860. PMID: 37716163

The preferred LMP7 antibody is LMP7 Antibody (A-12): sc-365699.